Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol MBIO
- Company Mustang Bio, Inc.
- Price $0.29
- Changes Percentage 35
- Change 0.0761
- Day Low $0.21
- Day High $0.3
- Year High $2.11
- Year Low $0.13
- Market Cap $10,679,643
- Price Avg 50 EMA (D) $0.27
- Price Avg 200 EMA (D) $0.62
- Exchange NASDAQ
- Volume 4,284,697
- Average Volume 1,103,367
- Open $0.21
- Previous Close $0.22
- EPS -2.72
- PE -0.11
- Earnings Announcement 2024-11-12 00:00:00
- Shares Outstanding $36,387,200
Company brief: MUSTANG BIO, INC. (MBIO )
- Healthcare
- Biotechnology
- Dr. Manuel Litchman M.D.
- https://www.mustangbio.com
- US
- N/A
- 08-22-2017
- US62818Q2030
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.